Noting its average daily volume at 1.79 million shares each day over the month, this signifies a pretty significant change over the norm. BB&T Securities LLC boosted its position in shares of Alexion Pharmaceuticals by 7.5% in the first quarter. Huntington National Bank increased its stake in shares of Alexion Pharmaceuticals by 1,084.6% in the second quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company's stock valued at $40,823,000 after acquiring an additional 4,115 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Alexion Pharmaceuticals by 0.4% during the 2nd quarter. Mariner Wealth Advisors LLC now owns 10,068 shares of the biopharmaceutical company's stock valued at $1,402,000 after buying an additional 1,508 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Alexion Pharmaceuticals in the second quarter worth $160,000. Finally, IFC Holdings Incorporated FL bought a new stake in Alexion Pharmaceuticals in the 3rd quarter valued at $861,000. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company's stock valued at $656,000 after acquiring an additional 4,861 shares during the last quarter. Nationwide Fund Advsr holds 0.09% in Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96.
Alexion Pharmaceuticals Inc. has 52 week low of $96.18 and a 52 week high of $149.34 with a PE ratio of 58.92 and has a market capitalization of $0. Alexion Pharmaceuticals Inc (Call) now has $25.73 billion valuation.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. They expect $1.09 EPS, down 0.91% or $0.01 from last year's $1.1 per share. The firm had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. After $1.28 actual EPS reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -14.84% negative EPS growth. The business's quarterly revenue was up 19.9% compared to the same quarter past year. During the same quarter in the prior year, the business posted $1.23 EPS.
COPYRIGHT VIOLATION NOTICE: "Crossmark Global Holdings Inc". COUGHLIN CHRISTOPHER J bought $234,200 worth of Alexion Pharmaceuticals, Inc. "(NASDAQ:ALXN)" was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of U.S. and global copyright legislation.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 127.52 on Tuesday. Also, Director Ann M. Veneman sold 835 shares of the stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the transaction, the director now owns 5,480 shares in the company, valued at $799,038.80. Canada Pension Plan Investment Board owned approximately 0.18% of Alexion Pharmaceuticals worth $55,091,000 as of its most recent filing with the Securities & Exchange Commission. The share price was last seen -1.49% lower, reaching at $113.45 on November 13, 2017. Following the completion of the sale, the executive vice president now directly owns 26,092 shares of the company's stock, valued at $3,794,820.48. The disclosure for this sale can be found here. Insiders have sold 16,490 shares of company stock valued at $2,337,251 in the last three months. Corporate insiders own 4.35% of the company's stock. (NASDAQ:ALXN). Envestnet Asset Mngmt, a Illinois-based fund reported 11,274 shares. TheStreet downgraded shares of Alexion Pharmaceuticals from a "b-" rating to a "c+" rating in a research report on Friday. Zacks Investment Research cut Alexion Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Wednesday, November 1st. Stifel Nicolaus lowered their target price on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a "buy" rating on the stock in a research note on Tuesday, October 24th. SunTrust Banks, Inc. reaffirmed a "buy" rating and issued a $180.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Six analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of "Buy" and an average target price of $154.01. British Columbia owns 0.16% invested in Alexion Pharmaceuticals, Inc. The Company's product line includes new and remanufactured automotive hard parts, such as alternators, starters, fuel pumps, water pumps, brake system components, batteries, belts, hoses, temperature control, chassis parts, driveline parts and engine parts; maintenance items, such as oil, antifreeze, fluids, filters, wiper blades, lighting, engine additives and appearance products, and accessories, such as floor mats, seat covers and truck accessories.